Oncology Clinical Decision Support Market (2026-2036)
The global oncology clinical decision support market was valued at USD 0.71 billion in 2026. This market is expected to reach USD 2.33 billion by 2036, growing at a CAGR of 12.6% during the forecast period 2026–2036.
- Published
- Jun 2026
- Pages
- 272
- Format
- PDF + Excel
- Report ID
- MRHC - 1042026
- Base year
- 2025
- 2026 · ESTIMATED
- $710.0M
- 2036
- $2.33B
- CAGR 2026–2036
- 12.6%
2025 baseline · 2026–2036 forecast at 12.6% CAGR · hover a bar for the value
Key highlights
The global oncology clinical decision support market is projected to reach USD 2.33 billion by 2036.
The market is expected to grow at a CAGR of 12.6% during the forecast period 2026–2036.
The global market is estimated at USD 0.71 billion in 2026.
AI in oncology is the fastest-growing technology segment, essential for interpreting genomic data.
Oncology decision support systems can reduce medication errors in cancer care by up to 40%.
Cloud-based SaaS models account for the largest share of the oncology decision support software market.
Precision oncology decision support tools can reduce treatment costs by 15-20% through improved therapy matching.
North America holds the largest market share, estimated at approximately 48% in 2026.
The volume of genomic data in oncology is doubling every 7-12 months, driving the need for automated support.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2036 |
| Market Size (2026) | USD 710.0 million |
| Market Size (2036) | USD 2.33 billion |
| CAGR (2026–2036) | 12.6% |
| Format | PDF, Excel & Cloud Portal · 272 pages |
| Segments Covered | By Product & Service: Software, Services · By Type: Knowledge-Based, AI/ML-Based · By Application · By End User |
| Key Companies | IBM Corporation, Oracle Corporation, Philips Healthcare, Elekta AB |
Report infographic
Market dynamics
7 factors across 5 forcesThe primary driver for the oncology
clinical decision support market is the increasing complexity of cancer treatment pathways, which increasingly rely on biomarker-driven therapies, companion diagnostics, immunotherapies, and precision medicine approaches. According to the International Agency for Research on Cancer, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022, while the global cancer burden is projected to increase by 77% by 2050, reaching more than 35 million new cases annually. As oncology care becomes more personalized, clinicians must evaluate growing volumes of genomic, clinical, and treatment data, creating significant demand for advanced clinical decision support tools.
Furthermore, the widespread adoption of electronic
health records (EHRs) has established the digital infrastructure necessary for CDSS deployment. According to the Office of the National Coordinator for Health Information Technology, nearly 96% of non-federal acute care hospitals and approximately 78% of office-based physicians in the United States have adopted certified EHR systems. Government initiatives supporting precision medicine and healthcare digitalization are also accelerating market growth. For example, the National Institutes of Health continues to invest through programs such as the All of Us Research Program, which has enrolled more than 1 million participants to advance personalized healthcare and precision medicine. The growing need to improve diagnostic accuracy, treatment selection, and patient safety in oncology is driving the widespread implementation of clinical decision support solutions across healthcare systems.
Table of contents
12 chapters · 105 sections · 272 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Product | Cloud-Based Software | Cloud-based Software |
| By Type | Knowledge-Based CDSS | Non-Knowledge Based CDSS (AI/ML) |
By Product
- Cloud-Based Software to Hold Largest Share
- The Cloud-based Software segment is expected to hold the largest share of the market.
- This dominance is driven by the scalability, ease of implementation, and lower total cost of ownership associated with SaaS models, making them the preferred choice for modern oncology practices.
- The Cloud-based Software segment is also projected to witness the fastest growth during the forecast period, as more institutions move away from legacy on-premise systems to more flexible and interoperable digital platforms.
By Type
- The Knowledge-Based CDSS segment is expected to hold the largest share of the market.
- These systems, which utilize rule-based algorithms following established clinical guidelines like NCCN, are the current standard of care and provide a high degree of transparency.
- The Non-Knowledge Based CDSS (AI/ML) segment is projected to witness the fastest growth.
- As the volume of genomic data increases, the need for machine learning models that can interpret complex biological patterns is becoming critical for precision oncology.
Geographic analysis
North America
Largest shareNorth America is expected to hold the largest share of the global oncology clinical decision support market in 2026, accounting for approximately 48% of the total revenue. This is due to high healthcare IT spending, a robust ecosystem of oncology research, and the presence of major industry players like Oracle, IBM (Merative), and Epic. The region's early adoption of precision medicine and favorable regulatory environment are also key drivers.
Asia-Pacific
Fastest growthAsia-Pacific is projected to witness the fastest growth during the forecast period. The region is modernizing its healthcare infrastructure at an unprecedented pace, with countries like China and India investing heavily in AI-driven healthcare solutions. The rising incidence of cancer and the need for efficient data management in large-scale clinical settings are the primary growth drivers. Key companies operating in the Asia-Pacific market include major global vendors and emerging local tech firms.
Competitive landscape
- IBM Corporation
- Oracle Corporation
- Philips Healthcare, Elekta AB
Frequently asked questions
The market is projected to reach USD 2.33 billion by 2036, growing at a CAGR of 12.6% from 2026 to 2036.
Cite this report
Meticulous Research. (2026). Oncology Clinical Decision Support Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 1042026). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/oncology-clinical-decision-support-market-6709